Hhlr Advisors, Ltd. Aligos Therapeutics, Inc. Transaction History

Hhlr Advisors, Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.35 - $1.07 $425,424 - $1.3 Million	1,215,498 Added 63.77%	3,121,689 $1.09 Million
Q4 2023 Feb 14, 2024	SELL	$0.56 - $0.8 $226,000 - $322,858	-403,573 Reduced 17.47%	1,906,191 $1.26 Million
Q4 2022 Feb 14, 2023	SELL	$0.89 - $28.0 $49,217 - $1.55 Million	-55,300 Reduced 2.34%	2,309,764 $2.19 Million
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $2.91 Million - $3.54 Million	200,000 Added 9.24%	2,365,064 $36.7 Million
Q4 2020 Feb 12, 2021	BUY	$13.2 - $32.74 $28.6 Million - $70.9 Million	2,165,064 New	2,165,064 $59.9 Million

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.57B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.